Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS and University of Saskatchewan Partner to Conduct Cannabinoid-Based Research on Possible Treatment of Brain Disorders","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"VIDO-InterVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ZYUS Collaborates with USask\u2019s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Launches HOPE (Human Osteoarthritis Pain Evaluation) Phase 1 First in Human Clinical Trials","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Aureuspharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ZYUS Life Sciences Partners with Portugal\u2019s Aureuspharma to Further Increase International Patient Access to Medical Cannabinoids","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Life Sciences Launches New Medical Cannabinoid Formulation for Direct to Patient Sales in Canada","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Announces Database Lock for its Phase 1 First-in-Human Clinical Trial","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin\u00ae Softgels","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase I","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase I"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences Gets USFDA Nod for Generic Heart Failure Treatment Drug","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Zydus Lifesciences gets USFDA Nod for Generic Cancer Treatment Capsules","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by ZYUS Life Sciences

    Menu

    ZYUS Life Sciences

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              ZYUS Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zydus Lifesciences gets USFDA Nod for Generic Cancer Treatment Capsules

              Details:

              Cyclophosphamide-Generic is a DNA cross-linker, small molecule, cytotoxic drug candidate, which is currently being evaluated for the treatment of lymphoma.

              Lead Product(s): Cyclophosphamide

              Therapeutic Area: Oncology Product Name: Cyclophosphamide-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ZYUS Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zydus Lifesciences Gets USFDA Nod for Generic Heart Failure Treatment Drug

              Details:

              USFDA approved generic version of Ivabradine, is a small molecule oral blocker of HCN channels, which is indicated to reduce the risk of hospitalisation for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with certain conditions.

              Lead Product(s): Ivabradine Hydrochloride

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Ivabradine-Generic

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 01, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ZYUS Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ZYUS Life Sciences Corporation Announces Positive Phase I Clinical Trial Results for Trichomylin® Softgels

              Details:

              Trichomylin softgels, a first-in-class drug product candidate formulated with a proprietary fixed-dose cannabinoid combination, has been specifically designed for the management of chronic pain.

              Lead Product(s): Cannabidiol,Cannabichromene,Tetrahydrocannabinol

              Therapeutic Area: Musculoskeletal Product Name: Trichomylin

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ZYUS Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ZYUS Announces Database Lock for its Phase 1 First-in-Human Clinical Trial

              Details:

              Trichomylin® softgels, is a proprietary novel fixed-dose cannabinoid formulation developed by ZYUS to alleviate chronic pain and has the potential to be a safe and effective alternative to opioids – without the devasting addictive qualities

              Lead Product(s): Trichomylin

              Therapeutic Area: Musculoskeletal Product Name: Trichomylin

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 15, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ZYUS Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ZYUS Life Sciences Launches New Medical Cannabinoid Formulation for Direct to Patient Sales in Canada

              Details:

              A new THC-dominant medical cannabinoid formulation, Zylem™ 20:1, for direct sales and distribution to registered medical patients across Canada as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients.

              Lead Product(s): Cannabinoid

              Therapeutic Area: Neurology Product Name: Zylem

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ZYUS Life Sciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ZYUS Life Sciences Partners with Portugal’s Aureuspharma to Further Increase International Patient Access to Medical Cannabinoids

              Details:

              Under the agreement, ZYUS’ cannabinoid formulations are expected to hit the Portuguese market as early as the second half of 2021. It's lead drug product candidate, Trichomylin® for pain management in a limited number of patients with osteoarthritis.

              Lead Product(s): Trichomylin

              Therapeutic Area: Musculoskeletal Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Aureuspharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership May 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ZYUS Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ZYUS Launches HOPE (Human Osteoarthritis Pain Evaluation) Phase 1 First in Human Clinical Trials

              Details:

              ZYUS Life Sciences will be launching a first-in-human (FIH) clinical trial on the safety, tolerability and efficacy of its lead drug product candidate, Trichomylin®, through its wholly owned subsidiary, ZYUS Life Sciences Australia Pty. Ltd.

              Lead Product(s): Trichomylin

              Therapeutic Area: Musculoskeletal Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ZYUS Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ZYUS Announces Positive Milestone in Plant-Based COVID-19 Vaccine Antigen Production

              Details:

              Preliminary research results from ZYUS Life Sciences show that plant-based antigens are reactive to anti-COVID-19 antibodies and potentially offer immunity from COVID-19.

              Lead Product(s): Plant-based COVID-19 antigen

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ZYUS Life Sciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ZYUS Collaborates with USask’s VIDO-InterVac to Develop a Plant-Based Vaccine for COVID-19

              Details:

              ZYUS will leverage its bio-pharmaceutical plant technology platform and expertise to develop and express a protein that VIDO-InterVac has identified as a potential antigen for a COVID-19 vaccine.

              Lead Product(s): Plant based vaccine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Vaccine

              Recipient: VIDO-InterVac

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              ZYUS Life Sciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ZYUS and University of Saskatchewan Partner to Conduct Cannabinoid-Based Research on Possible Treatment of Brain Disorders

              Details:

              Pre-clinical study seeks to determine the impact of cannabis derivatives on mental health conditions.

              Lead Product(s): Cannabis derivatives

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY